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Is total hip arthroplasty safely performed in
lung transplant patients? Current
experience from a retrospective study of
the Zurich lung transplant cohort
Jürgen W. Schmitt1,4*, Christian Benden2, Claudio Dora3 and Clément M.L. Werner1
Abstract
Background: In recent years, the number of lung transplants has increased rapidly, with higher quality of life and
improved survival rates in transplant recipients, including patients with advanced age. This, in turn, means that more
transplant recipients will seek musculoskeletal care to treat degenerative joint disease and also trauma incidents. Safety
concerns regarding elective and posttraumatic hip arthroplasty in transplant patients include an increased risk of
infection, wound healing problems, periprosthetic fractures and loosening of the implants.
Methods: Clinical outcomes and safety aspects were retrospectively reviewed for five primary total hip arthroplasties
(THA) in lung transplant recipients with minimal follow-up of two years at average of 2.6 (2–11) years. Patients were
recruited from the Zurich Lung Transplant Center comprising of a cohort of 253 patients between January 1st, 2004
and December 31st, 2013.
Results: All five patients subjectively reported excellent outcomes after THA with a final average Harris Hip Score of 97
(86–100). One 71-year-old patient died 26 months after THA unrelated to arthroplasty. One superficial wound healing
disturbance was documented. No periprosthetic fractures, no dislocations, no periprosthetic infections, no further revision
surgery, no implant loosening was observed.
Conclusions: In conclusion, THA can be safely and successfully performed even in lung transplant patients
under long-term immunosuppressive therapy and polymedication, provided a multidisciplinary approach can
be granted.
Keywords: Hip arthroplasty, Lung transplantation, Immunosuppression, Antibiotic treatment, Osteonecrosis,
Safety, Complications
Background
In recent years, the number of lung transplants has in-
creased rapidly, with improved survival rates in transplant
recipients, including patients with advanced age [1]. Lung
transplant patients require triple life-long immunosuppres-
sion with steroids, as well as immunosuppressive agents
preventing graft rejection. These medications have distinct
side effects and can complicate medical and surgical
treatment.
Lung transplant patients are vulnerable to medical
complications also affecting the musculoskeletal system
[1, 2]. Long-lasting and high-dose steroid use can lead to
symptomatic osteonecrosis of the bones, particularly the
femoral head [3–5]. Severe osteonecrosis can lead to
subchondral fractures and collapse of the femoral head
following total hip arthroplasty (THA) [5]. Despite the
risks of complications associated with lung transplants
and other solid organ transplants, the number of trans-
plants continues to rise, and with it, regardless of immuno-
suppression, an improved post-transplant quality of life and
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better chances of long-term survival. This, in turn, means
that more transplant recipients will seek musculoskeletal
care to treat degenerative joint disease and also (osteopor-
otic) trauma incidents.
Safety concerns regarding elective and posttraumatic
arthroplasty in transplant patients include the potential
risk of perioperative complications, especially an increased
risk of infection and wound healing problems due to life-
long immunosuppression [5–7]. There is also an increased
risk of periprosthetic fractures and loosening, due to
osteoporosis and secondary bone loss [2, 8–10].
With regard to transplant patients, it is still under
debate which special medical and surgical management
approaches could benefit from closer inspection.
Outcomes of THA have been reported in cardiac
[6, 11, 12], liver [6, 7, 13–16], and mostly in renal
transplants [5–7, 13, 17–25]. In the literature, there
are few guidelines regarding particular perioperative
precautions and postoperative care after hip arthro-
plasty in lung transplant patients [26, 27].
The purpose of this review was to examine the peri-
operative workup and outcome of THA in lung trans-
plant recipients in the Zurich cohort.
Methods
This is a retrospective study of all patients who underwent
primary THA following lung transplantation at the
University Hospital of Zurich between January 1st,
2004 and December 31st, 2013. During this period, in
total 253 lung transplantations were done. Five THA in
five lung transplant patients were identified (Table 1).
Transplantation was performed in the study patients
for the following underlying diseases: cystic fibrosis
(CF), chronic obstructive pulmonary disease (COPD),
idiopathic pulmonary arterial hypertension (IPAH) and
lymphangioleiomyomatosis (LAM).
All patients were prepared well in advance for the
THA by their lung transplant specialists. Patients
underwent extensive cardiopulmonary testing, in-depth
anaesthesia assessment and specific infectious disease
workup. They were evaluated for their specific risks
due to previous infectious issues including chronic bac-
terial and viral infections. In general, preoperative IV
antibiotic treatment was initiated at least 24 h prior to
surgery. Mostly, a dual regimen of piperacillin/tazobac-
tam and teicoplanin was used empirically.
Patients continued on their transplantat-specific, mostly
triple immunosuppressant regimen of the following drugs:
cyclosporine, mycophenolic acid and corticosteroid pre-
and postoperatively. In addition, patients were kept on their
usual prophylactic antibiotic (pneumocystis pneumonia
(PCP)), antiviral and antifungal agents.
Extremity preparation within the operative suite under
laminar flow included electric clipping of hair, three-fold
antiseptic scrub with alcohol disinfectant, followed by
draping with sterile adhesive polyurethane film (Opsite).
Two experienced orthopedic surgeons performed the
procedures.
Following surgery, the patients were observed in IMCU
or ICU. Postoperative antibiotic prophylaxis was given at
least until wound healing confirmed. All patients received
standard deep vein thrombosis prophylaxis, including
compression stockings and low-molecular weight heparin,
continuing for 6 weeks after operation.
Clinical and radiological follow-ups were obtained after
6 weeks, 3, 6, 12 and 24 months by the orthopaedic sur-
geons, in cooperation with their lung transplant specialists.
All multidisciplinary patient charts related to the arthro-
plasty were analysed. Specific outcome measures included
VAS, validated functional Harris Hip Score (HHS), subject-
ive hip value, gait function and complications. All patients
had a minimal follow-up of 24 months.
The Institutional Review Board approved the study
(KEK-ZH-Nr. 2011–0320).
Results
Between 2004 and 2013, five primary THAs were per-
formed in 4 females and 1 male lung transplant recipients.
Age at transplant was 36.2 (14.2–66.5) years. Three patients
with avascular necrosis (AVN) of the femoral head pre-
sented markedly limited hip function with severe pain that
failed to improve with conservative treatment. One patient
suffered from the cut-out of cancellous screws through the
femoral head, due to posttraumatic AVN after osteosynth-
esis of a femoral head fracture with three cannulated can-
cellous screws. One patient presented a pathologic femoral
neck fracture caused by enchondroma. Hence, there was a
time interval of 9.4 (2.4–12.2) years between lung trans-
plant and THA. Arthroplasty was performed at an average
age of 47.2 (23.6–69.0) years.
All five patients demonstrated relevant medical issues
and preoperative comorbidities. ASA physical status was
an average value of 2.8 (2–4). Most commonly, the patients
suffered from chronic lung allograft dysfunction (CLAD),
hypertension, diabetes mellitus, pancreatic insufficiency,
chronic kidney disease, chronic transplant rejection and
chronic infections (chronic cytomegalovirus (CMV) infec-
tion, chronic carrier Noro-virus (3 patients), throat swap
multi drug-resistant Pseudomonas (1 patient)).
Anaesthesia type was mainly general anaesthesia (four
general, one spinal). Two approaches for THA were uti-
lized: anterior “Modified Hueter” approach and lateral
Hardinge approach. In more complex reconstructive sit-
uations, the lateral approach was favoured, providing a
better intraoperative overview and options. In standard
situations, an anterior minimal invasive approach was
given priority due to its obvious advantages. Acetabular
components were cemented using the Apricot highly
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Table 1 Patient characteristics
Patient Sex Age y Joint indication Approach Immunosuppression Antibiotic prophylaxis Hospital stay d Interval y F/U y Subjective
hip value %
Harris Hip
Score (HHS)
points
Perioperative
complications
Prosthetic
complications
MJ f 47 Posttraumatic AVN Hardinge CYA, MMF, PRED CIP 7 11.0 11.1 90 86 None None
SB f 42 AVN Hardinge CYA, MMF, PRED TZP, TEC, CIP 39 12.2 3.1 100 100 Wound healing
disturbance
None
SS m 23 Posttraumatic AVN Hardinge CYA, MMF, PRED TEC, MER (INN) 16 9.4 2.0 100 97 None None
MH f 62 Pathologic Fx AMIS CYA, MMF, PRED TZP, TEC, CIP 11 3.1 2.6 90 100 None None
FS f 68 AVN AMIS CYA, MMF, PRED TZP, TEC 8 2.4 2.0 100 95 None None
AVN Avascular necrosis, Fx Fracture, Hardinge Hardinge approach, AMIS Anterior minimal invasive surgery – modified Hueter approach, CYA Cyclosporine A, TAC Tacrolimus, MMF Mycophenolate Mofetil, PRED
Prednisone, CIP Ciprofloxacin, MER Meropenem, TEC Teicoplanin, TZP Piperacillin/Tazobactam, INN Amoxicillin/Clavulanic acid, Interval Time from lung transplantation to total hip arthroplasty, F/U Follow-up time
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cross-linked polyethylene cup (Medacta international,
Castel San Pietro, Switzerland) and Palacos® R + G bone
cement (Heraeus Medical, Wehrheim, Germany)) in all
patients (Fig. 1). In one patient, a Ganz reinforcement
ring with hook (Zimmer Inc. Warsaw IN, USA) was
used in addition (Fig. 2). Femoral stems were uncemen-
ted in three cases and cemented in two procedures, due
to poor bone quality and pathologic fracture. Femoral
heads ranged from size 28 to 32 mm cobalt-chrome
heads. Operation time averaged 130 (70–155) min with
no intra-operative complications. Average estimated
intraoperative blood loss was 400 (200–800) mL. One
single redon drainage was used in 80 % of cases. Pre-
operative haemoglobin was 121 (98–138) gL. Postopera-
tively, blood transfusions had to be administered in four
cases. Full weight bearing was allowed in THA with
minimal-invasive anterior “Modified Hueter” approach.
During hospital stay all patients received prolonged
prophylactic antibiotic treatment with different medication
over 21 (3–35) days. All patients had thromboembolic
prophylaxis for six weeks. The postoperative course was
complicated in one patient with difficult wound healing
with development of a subcutaneous fistula of the absorb-
able suture after 11 weeks (77 d) requiring operative super-
ficial revision of soft tissue. Length of hospital stay was 11
(7–39) days. No periprosthetic fractures, no dislocations,
no periprosthetic infections, no further revision surgery, no
implant loosening were observed (Fig. 1). One 71-
year-old patient died 26 months after THA unrelated
to arthroplasty.
Clinical and radiological follow-up postoperatively was
available at an average of 2.6 (2–11) years. All patients
were very satisfied and self-reported their subjective hip
value of 100 (90–100) %. Average Harris Hip Score was
97 (86–100) points. One patient suffered from mild peri-
trochanteric pain, without limping.
Discussion
As the number of patients undergoing lung transplantation
increases, there will be a higher frequency of arthroplasties
for osteonecrosis, trauma or degenerative osteoarthritis, in
order to improve quality of life of transplant recipients.
Perioperative management requires a multidisciplinary
approach of trained orthopedic surgeons, lung transplant
specialists and specialized anaesthesiologists. It is our
policy to directly involve the lung transplant team during
the whole hospital stay in the perioperative care of these
complex patients.
We observed a low incidence of hip arthroplasty (5 THA
in 253 lung transplantations) over a period of 10 years at
Fig. 1 3-year-follow up after THA in 46-year-old lung transplant patient
Fig. 2 11-year-follow up after THA in 58-year-old lung transplant
patient. Ganz reinforcement ring with hook was used because of
poor bony quality in the acetabulum
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the Zurich Lung Transplant Cohort that is probably due to
the meticulous and close follow-up management of lung
transplant patients at our Institution. Furthermore, adapta-
tion of immunosuppression for each individual lung trans-
plant patient is mandatory to titrate to the lowest dose of
the immunosuppression to prevent allograft rejection, how-
ever, avoid overimmunosuppression causing infection and
poor wound healing. Cyclosporine A, mycophenolate
mofetil and prednisone were predominantly used. All
patients were prescribed daily medication between 5
and 7.5 mg prednisone accordingly 0.1–0.15 mg/kg/day
beyond 12 months after transplantation [27]. The risk
of osteonecrosis is less than 3 % when the dosage is
kept below 15 mg of prednisone per day [12, 28]. Im-
munosuppressive drugs such as cyclosporine A help to
decrease the risk of avascular necrosis [28]. In the lit-
erature, prevalence of osteonecrosis of the femoral head
after organ transplantation ranges between 2 and 41 %
[4, 5, 29]. Potential reasons for this wide variation are
differences in steroid regimens and in the sensitivities
of screening modalities including inability to capture data
(MRI) on asymptomatic patients. However, the authors are
unable to estimate the true incidence of femoral head ne-
crosis in the patient cohort of lung transplant recipients.
Otherwise, corticosteroids and immunosuppressive medi-
cation cause osteoporosis [2]. The loss of bone mineral
density (BMD) is most evident in the first year after trans-
plantation, with a fracture rate up to 29 % [2] when high
doses of steroids and immunosuppressives are needed to
prevent acute organ rejection [8–10]. Most common frac-
ture sides are vertebral compression fractures [2]. In our
cohort, we observed one femoral fracture after a cycling
accident 6.4 years after lung transplantation, and one
pathological fracture after three years because of benign
enchondroma in the femoral neck. Our prophylactic medi-
cation augmenting bone density includes mainly calcium
and vitamin D supplementation, and bisphosphonates
based on bone mineral density assessment.
To prevent postoperative infection in patients with
triple immunosuppression is of major importance. In
our collective, there was one case of superficial wound
healing disturbance. After 11 weeks, the patient suf-
fered from small subcutaneous fistula of absorbable su-
ture and was treated with operative spindle-shaped
incision followed by an extended course of intravenous
antibiotics. The literature reports a higher incidence of
periprosthetic infection in transplant patients, with
rates varying from no increase, to rates up to 19 % in-
fections in various publications [5, 7, 25]. Vergidis et al.
report 12 periprosthetic joint infections in 365 patients
(3.4 %) [6]. Most data is mostly available from renal
transplant patients. Ledford et al. reported in his col-
lective of 15 THA in 10 lung transplant recipients, no
periprosthetic infections or revision surgeries [26].
Wide variance of results and small patient populations
make it difficult to establish a definitive consensus of
antibiotic treatment in these immunocompromised pa-
tients. In the literature, no guidelines regarding type and
duration of antibiotic treatment exist. In some studies,
antibiotic prophylaxis with cephalosporines was used
predominantly for 24 h [14, 26]. In one other study, anti-
biotic prophylaxis was mainly cephalosporines or vanco-
mycin over 6 weeks [6]. We strongly support prolonged
appropriate antibiotic treatment until entire wound heal-
ing occurs. Teicoplanin, piperacillin and ciprofloxacin
were predominantly used in combination. Drug inter-
action with immunosuppression and potential side ef-
fects should be carefully considered [27]. Duration of
postoperative antibiotic treatment averaged 21 (3–35)
days. Preoperative intravenous antibiotic treatment was
started at least 24 h before surgery.
In our case series, the transfusion rate was very high.
Despite the intraoperative blood loss being an average of
400 mL, during the postoperative course four patients
received a blood transfusion for symptomatic anemia be-
tween the first and 5th postoperative day. The decision
to transfuse was based on clinical symptoms and in con-
junction with the recommendation by the lung trans-
plant team. First hemoglobin after 24 h counted on average
98 (72–113) gL. High frequency of blood transfusions likely
reflects the relative inability of lung transplant patients to
tolerate a combination of fluid imbalance and minor
fluctuations in hemoglobin levels postoperatively, be-
cause of restricted pulmonary function due to impaired
lymphatic drainage. Furthermore, preoperative chronic
anemia (hemoglobin 123 gL), low body weight (51 kg)
and low BMI (19.7 kg/m2) in our population in com-
bination with the expected intraoperative blood loss,
may result in increased postoperative need for blood
transfusion. Patients received, on average 2 units of blood.
Other studies report a transfusion rate of 66 % in lung
transplant patients [26] and lower rates (39 %) in liver
transplant patients [14] after THA. We assume that a low
threshold for transfusion is important in this special
population, given the inability of lung transplant recipi-
ents to tolerate even minor fluctuations in hemoglobin
levels postoperatively.
As expected, length of hospital stay in this population
was higher than uncomplicated primary THA due to
significant comorbidities of the patients. Prolonged intra-
venous antibiotic treatment and special inpatient recom-
mendations of the lung transplant team to facilitate a safe
hospital inpatient stay lead to a longer hospital stay. In
our population, we had just a minor complication, nor
periprosthetic infections and major medical complica-
tions. Responsible medical staff noticed special attention
being given to special perioperative precautions in lung
transplant patients (Table 2).
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In our cohort, one 71-year-old patient died 26 months
after THA (4.6 years after lung transplantation) because
of progressive CLAD. The only publication from Ledford
et al. of a lung transplant patient cohort with THA re-
ported a high mortality rate in 3 patients (33 %) at time
of follow-up after 27.5 months [26]. It is difficult to draw
specific conclusions based on these data due to the
shortened life expectancy could be related to other med-
ical comorbidities and small patient cohort.
To the authors’ knowledge, there are no reports in the
literature of THA in lung transplant patients using
minimal-invasive anterior approach. In two of our
cases, we used this anterior “Modified Hueter” approach
without any difficulties intra-operatively. Special care
requires precise exposure of the femoral entrance after
capsular release avoiding periprosthetic shaft and greater
trochanteric fractures due to poor bone quality.
Another controversial technical issue is THA fixation
in lung transplant recipients [20]. Generally, patients
require triple life-long immunosuppression including
steroids. Prolonged corticosteroid use is a significant risk
factor for periprosthetic fractures and loosening of the
implants due to osteoporosis and secondary bone loss
[2, 8–10, 28]. Cemented acetabular and femoral compo-
nents were used based on intraoperative assessment of
weakened bone that will not allow press-fit technique.
Since this was the case in all our patients, we cemented
all acetabular components; in fact, in one additional
patient, an acetabular roof reinforcement ring with hook
was used. Femoral stems were uncemented in 3 cases
and cemented in 2 procedures. We believe in the benefit
of cemented implants, especially in the acetabulum,
because of the perpetual steroid medication. Intraoperative
acetabular and femoral fractures have to be avoided. Re-
garding cemented THA, Goffin et al. report on revision-
free survival for all implants on 98.8 % at 10 years in renal
transplant patients [20]. In contrast, recent evidence sug-
gests that uncemented hip arthroplasty in renal transplant
recipients have similar survivorship [5, 17, 30]. Ledford et
al. used, in his collective of 15 THA in 10 lung transplant
recipients, cementless implants [26]. In our population, no
THA dislocation or loosening of the implants were
observed during follow-up.
A limitation of our study includes small numbers of
patients, midterm follow-up and its retrospective design.
Conclusions
In conclusion, THA can be safely and successfully per-
formed even in lung transplant patients, provided a
multidisciplinary approach can be granted.
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Table 2 Perioperative precautions relating to arthroplasty in lung transplant patients (adapted from Schuurmans et al. [27])
1 Exhaustion of conservative treatment, interdisciplinary approval of operative treatment, “No standard indications for non-standard patients!”
2 Meticulous preparation of procedure with all involved specialists that may be relevant (including lung transplant specialist, experienced surgeon,
specialized anesthetist, experienced intensive care physician for possible postoperative care)
3 Additional intravenous anti-infective treatment for at least one day before and prolonged after arthroplasty
4 Early and consequent laxative treatment to prevent intestinal complications. Avoid opioids.
5 Cautious blood pressure control and accurate fluid management. Arterial hypertension is highly prevalent among lung transplant patients.
Preoperatively no restricted fluid intake to avoid hemodynamic instability and renal dysfunction. Fluid overload should be avoided intra-operatively
due to impaired lymphatic drainage
6 Low threshold for transfusion postoperatively
7 Strict anti-reflux measures to prevent gastro-esophageal reflux and aspiration
8 Preventive strategies including intensive care unit bed ‘on standby’ after surgery
9 Anticipation of high likelihood of possible complications (kidney failure, hematoma, wound healing disturbance, delirium
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